Our
stock picking system has picked GENR(Genaera Corp.) today. The simulation
software will buy this stock on
Jun
30, 2006 at OPEN price. Our Loss Stop
is at -28% Do not hold if stock drops more than 28%. Please visit us
tomorrow after 9 o'clock for the next move.
Please see the below signals for the next trading day
JUNE 2006
Symbol
Alert Date
Entry Price
Exit Date
Exit Price
VOLUME
Profit/Loss
NOVL
02-Jun-06
6.29
15-Jun-06
5.82
18181272
-7.5%
REV
05-Jun-06
1.77
13-Jun-06
1.27
22606400
-28%
ERHE
07-Jun-06
0.39
09-Jun-06
0.49
2301806
25.6%
PARL
09-Jun-06
18.50
14-Jun-06
21.73
1588100
17.5%
RBAK
12-Jun-06
18.54
14-Jun-06
19.20
5816014
3.6%
ANAD
12-Jun-06
6.51
15-Jun-06
6.61
1364528
1.5%
TASR
13-Jun-06
7.69
15-Jun-06
8.08
4411384
5.1%
DXCM
13-Jun-06
13.99
19-Jun-06
13.59
3275552
-2.9%
TGAL
13-Jun-06
0.38
15-Jun-06
0.399
1979198
5.0%
QTWW
13-Jun-06
2.96
16-Jun-06
3.10
1144777
4.7%
SNMX
14-Jun-06
12.11
16-Jun-06
13.78
1428100
13.8%
PAYD
20-Jun-06
0.515
27-Jun-06
0.57
3261015
10.7%
OSCI
28-Jun-06
0.83
HOLD
9965300
-
IIP
28-Jun-06
0.91
SELL @ OPEN
888347
-
GENR
29-Jun-06
BUY @ OPEN
2705900
-
MAY
2006
Symbol
Alert Date
Entry Price
Exit Date
Exit Price
VOLUME
Profit/Loss
DOVP
27-Apr-06
8.13
02-May-06
8.18
875147
0.6%
PQE
01-May-06
12.4
06-May-06
11.50
4116700
-7.3%
VERT
02-May-06
0.33
05-May-06
0.35
2724765
6.1%
ECPN
07-May-06
2.64
11-May-06
2.80
2579084
6.1%
XSUNX
10-May-06
1.05
12-May-06
1.35
9458137
28.6%
MAG
12-May-06
2.66
22-May-06
2.33
1384200
-12.4%
IOTN
16-May-06
8.18
30-May-06
7.92
3842400
-3.2%
STTK
16-May-06
0.33
18-May-06
0.35
2966200
6.1%
EYTC
16-May-06
0.45
19-May-06
0.41
1084900
-8.9%
CAMH
24-May-06
1.60
26-May-06
1.99
1351762
24.4%
BCGI
24-May-06
1.21
30-May-06
1.36
947771
12.4%
May 2006 Performance
Number of Picks
11
Accuracy Rate
64%
Cumulative Return
54.7%
To see our recent history in 2006 please click here.
COMPANY INFORMATION
Oscient Pharmaceuticals Corp.
1000 Winter Street
Suite 2200
Waltham, MA 02451
United States
Phone: 781-398-2300
Fax: 781-893-9535
Web Site: http://www.oscient.com
Sector:
Healthcare
Industry:
Diagnostic Substances
Full Time Employees:
329
Oscient Pharmaceuticals Corporation, a biopharmaceutical company, engages in the
clinical development and commercialization of therapeutics to serve medical
needs in the United States. Its lead product fluoroquinolone antibiotic FACTIVE
tablets are used for the treatment of community-acquired pneumonia and acute
bacterial exacerbations of chronic bronchitis. The company’s product also
comprises Ramoplanin, a Phase II clinical trial completed product, which would
be used for the treatment of clostridium difficile-associated disease. Oscient
Pharmaceuticals’ preclinical development program includes an oral peptide
deformylase inhibitor for the treatment of respiratory tract infections. The
company also co-promotes TESTIM gel, a topical 1% testosterone gel, indicated
for the treatment of male hypogonadism. It also has pharmaceutical alliances
with bioMerieux, Schering-Plough, and Wyeth, which focuses on the development of
novel therapeutics and diagnostics for chronic human diseases and infectious
diseases. Oscient Pharmaceuticals was founded in 1961 and is headquartered in
Waltham, Massachusetts.
Internap Network Services Corp.
250 Williams Street
Atlanta, GA 30303
United States
Phone: 404-302-9700
Fax: 404-475-0520
Web Site: http://www.internap.com
Sector:
Technology
Industry:
Internet Service Providers
Full Time Employees:
330
Internap Network Services Corporation offers products and services that provide
Internet connectivity solutions to business customers who require network
availability for business applications, such as e-commerce, video and audio
streaming, voice over Internet protocol, virtual private networks, and supply
chain management. Its products and services are delivered by IP access services,
such as colocation and data center services, content distribution networks, and
managed security services, as well as pre and post installation services and
consulting. The company provides managed intelligent routing services; data
center services; flow control platform, a premise-based routing product for
customers who run their own multiple network installations; flow control
Xcelerator, an appliance that accelerates the performance of applications across
wide area networks and reduces the effects of network latency; and BusinessNet
services, a managed data acceleration service, for business-to-consumer
customers who deploy large files over long distances, such as from the United
States to Asia. In addition, it offers managed Internet services via third
parties, including Akamai CDN services; virtual private networking; and managed
security services, including Verisign intrusion detection/prevention and managed
firewall services. As of December 31, 2005, the company delivered services
through its 38 network access points in North America, Europe, Asia, and
Australia. It offers its products and services to customers in the financial
services, government, travel/hospitality, manufacturing, media/entertainment,
technology, and retail sectors. Internap Network Services Corporation was
founded in 1996 and is headquartered in Atlanta, Georgia.
RECENT PERFORMANCE
Dec 2005
21.6%
Jan 2006
41%
Feb 2006
-3.9%
Mar 2006
90%
Apr 2006
283%
May 2006
54.7%
COMPANY INFORMATION
Genaera Corp.
5110 Campus Drive
Plymouth Meeting, PA 19462
United States
Phone: 610-941-4020
Fax: 610-941-5399
Web Site: http://www.genaera.com
Sector:
Healthcare
Industry:
Biotechnology
Full Time Employees:
46
Genaera Corporation, a biopharmaceutical company, engages in the research and
development of medicines with focus on antiangiogenesis and respiratory
diseases. The company’s primary product EVIZON is under Phase II and Phase III
clinical trials to treat ophthalmic indications, specifically the ‘wet’ form of
age related macular degeneration. It is also developing Squalamine Lactate, a
Phase II clinical trail product, for the treatment of cancerous solid tumors;
LOMUCIN, a Phase II clinical trail product, to treat the overproduction of mucus
secretions involved in chronic respiratory disease; and interleukin-9 antibody,
a respiratory treatment based on the discovery of a genetic cause of asthma. In
addition, the company has various discovery research programs focused on the
treatment of obesity, infectious diseases, and inflammatory disorders. The
company has a collaborative agreement with MedImmune, Inc. to develop and
commercialize interleukin-9. Genaera Corporation was incorporated in 1987 and is
headquartered in Plymouth Meeting, Pennsylvania.
SIMULATION
PERFORMANCE RESULTS HAVE INHERENT LIMITATIONS, THE PERFORMANCE
TABLES AND RESULTS ARE BASED ON BACKTESTING OF CERTAIN TRADING
STRATEGIES. DO NOT REPRESENT TRADING IN ACTUAL ACCOUNTS You may have more losses or profits in your account comparing to other
member accounts due to many factors, including but not limited to: you and
other people may trade stock picks in different orders, orders not get
filled or partially get filled, selective trading some specific stock picks
instead of all stock picks, paying different commission fees required by
different brokerages, stock positions entered and exited at different price
other than our suggested price due to market orders, order execution
delayed, various human decisions or technical failures.
You
may lose all of your money when investing and trading in the stock markets! The data contained in the reports within this site is provided for
informational purposes only. It should not be viewed as a solicitation for
the referenced system or vendor. While the information and statistics given
are believed to be complete and accurate, we cannot guarantee their
completeness or accuracy. As past performance does not guarantee future
results, these results may have no bearing on, and may not be indicative of,
any individual returns realized through participation in this or any other
investment. No part of this document should be considered apart from the
Disclosure Statements contained herein.
